$CELG Recent Headlines
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 12:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 1:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 12:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 6:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 10:20 a.m. July 1, 2014 - Michael Ashbaugh
S&P, Dow rattle cage on uncharted territory 9:54 a.m. July 1, 2014 - Michael Ashbaugh
Celgene's fourth stock split is a hit with investors as shares climb 12:02 p.m. June 19, 2014 - Russ Britt
'Mad Money' Lightning Round: I'm Not Crazy About Sysco Anymore 6:00 a.m. Today - TheStreet.com
Cramer's Lightning Round - Celgene Is A Monster (11/3/14) 5:37 a.m. Today - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Merger Monday Has Returned 8:14 p.m. Nov. 3, 2014 - TheStreet.com
Big Cap 20: Health Care, Tech Stocks Rule The Roost 4:58 p.m. Nov. 3, 2014 - Investors Business Daily
Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock 3:53 p.m. Nov. 3, 2014 - Seeking Alpha
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks 11:57 a.m. Nov. 3, 2014 - TheStreet.com
Was That The Final Growth Stock Shakeout? 11:23 a.m. Nov. 3, 2014 - Seeking Alpha
Trade of the Day: Celgene (CELG) Stock is a Stellar Buy at $100 7:21 p.m. Nov. 2, 2014 - InvestorPlace.com
Top Stocks Sold as Insiders Take Advantage of Huge Market Rally 8:42 a.m. Nov. 1, 2014 - 247WallSt.com
'Fast Money' Recap: Will Japan's Stimulus Lead to U.S. Deflation? 5:00 a.m. Nov. 1, 2014 - TheStreet.com
IBD 50 Caps Impressive 2-Week Rally 5:47 p.m. Oct. 31, 2014 - Investors Business Daily
Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX 6:00 a.m. Oct. 31, 2014 - TheStreet.com
Cramer's Mad Money - Charles River Labs Battles Ebola (10/30/14) 5:46 a.m. Oct. 31, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong 8:11 p.m. Oct. 30, 2014 - TheStreet.com
InsiderInsights.com Daily Round Up 10/29/14: JMP, UFI AIRT, COG 7:25 a.m. Oct. 30, 2014 - Seeking Alpha
Cramer's Mad Money - Eaton Says Slow Growth Is The New Normal (10/29/14) 7:07 a.m. Oct. 30, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Stay Away From Applied Materials 6:00 a.m. Oct. 30, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Where to Find Bargains Created by the Fed 8:12 p.m. Oct. 29, 2014 - TheStreet.com
3 Stocks Reiterated As A Buy: CAT, CELG, MET 2:44 p.m. Oct. 29, 2014 - TheStreet.com
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog 12:28 p.m. Oct. 29, 2014 - Zacks.com
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX
Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene 9:10 a.m. Oct. 15, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis 8:38 a.m. Oct. 10, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis 8:37 a.m. Oct. 10, 2014 - BusinessWire - BZX
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By InvestorsObserver 9:31 a.m. Oct. 8, 2014 - PR Newswire - PRF
Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress 7:30 a.m. Oct. 7, 2014 - BusinessWire - BZX
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Third Quarter 2014 Results on October 23, 2014 8:30 a.m. Oct. 1, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis 3:18 p.m. Sept. 23, 2014 - BusinessWire - BZX
Zeldes Haeggquist & Eck, LLP Announces Investigation of Celgene, Inc. 9:01 a.m. Sept. 22, 2014 - BusinessWire - BZX
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
Celgene Appoints Tuomo Pätsi as President of EMEAand Commits to Continue Delivering Innovative Solutionsto Meet Patient Needs Across the Region 8:02 a.m. Sept. 19, 2014 - BusinessWire - BZX
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers 9:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
Critical Alerts For CBS, Imperva Inc, Toyota Motor, Celgene and News Corp Released By InvestorsObserver 9:31 a.m. Sept. 11, 2014 - PR Newswire - PRF
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth 8:55 a.m. Sept. 8, 2014 - PR Newswire - PRF
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology 9:06 a.m. Sept. 5, 2014 - ACCESSWIRE
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen 8:55 a.m. Sept. 4, 2014 - PR Newswire - PRF
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 12:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 1:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 12:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 6:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 10:20 a.m. July 1, 2014 - Michael Ashbaugh
S&P, Dow rattle cage on uncharted territory 9:54 a.m. July 1, 2014 - Michael Ashbaugh
Celgene's fourth stock split is a hit with investors as shares climb 12:02 p.m. June 19, 2014 - Russ Britt
'Mad Money' Lightning Round: I'm Not Crazy About Sysco Anymore 6:00 a.m. Today - TheStreet.com
Cramer's Lightning Round - Celgene Is A Monster (11/3/14) 5:37 a.m. Today - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Merger Monday Has Returned 8:14 p.m. Nov. 3, 2014 - TheStreet.com
Big Cap 20: Health Care, Tech Stocks Rule The Roost 4:58 p.m. Nov. 3, 2014 - Investors Business Daily
Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock 3:53 p.m. Nov. 3, 2014 - Seeking Alpha
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks 11:57 a.m. Nov. 3, 2014 - TheStreet.com
Was That The Final Growth Stock Shakeout? 11:23 a.m. Nov. 3, 2014 - Seeking Alpha
Trade of the Day: Celgene (CELG) Stock is a Stellar Buy at $100 7:21 p.m. Nov. 2, 2014 - InvestorPlace.com
Top Stocks Sold as Insiders Take Advantage of Huge Market Rally 8:42 a.m. Nov. 1, 2014 - 247WallSt.com
'Fast Money' Recap: Will Japan's Stimulus Lead to U.S. Deflation? 5:00 a.m. Nov. 1, 2014 - TheStreet.com
IBD 50 Caps Impressive 2-Week Rally 5:47 p.m. Oct. 31, 2014 - Investors Business Daily
Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX 6:00 a.m. Oct. 31, 2014 - TheStreet.com
Cramer's Mad Money - Charles River Labs Battles Ebola (10/30/14) 5:46 a.m. Oct. 31, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong 8:11 p.m. Oct. 30, 2014 - TheStreet.com
InsiderInsights.com Daily Round Up 10/29/14: JMP, UFI AIRT, COG 7:25 a.m. Oct. 30, 2014 - Seeking Alpha
Cramer's Mad Money - Eaton Says Slow Growth Is The New Normal (10/29/14) 7:07 a.m. Oct. 30, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Stay Away From Applied Materials 6:00 a.m. Oct. 30, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Where to Find Bargains Created by the Fed 8:12 p.m. Oct. 29, 2014 - TheStreet.com
3 Stocks Reiterated As A Buy: CAT, CELG, MET 2:44 p.m. Oct. 29, 2014 - TheStreet.com
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog 12:28 p.m. Oct. 29, 2014 - Zacks.com
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX
Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene 9:10 a.m. Oct. 15, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
New Analyses of Oral OTEZLA® (Apremilast) Presented at EADV Show Efficacy in Difficult-to-Treat Areas of Moderate to Severe Plaque Psoriasis 8:38 a.m. Oct. 10, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Data Presented at EADV Show Improved Measures of Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Plaque Psoriasis 8:37 a.m. Oct. 10, 2014 - BusinessWire - BZX
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By InvestorsObserver 9:31 a.m. Oct. 8, 2014 - PR Newswire - PRF
Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress 7:30 a.m. Oct. 7, 2014 - BusinessWire - BZX
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Third Quarter 2014 Results on October 23, 2014 8:30 a.m. Oct. 1, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis 3:18 p.m. Sept. 23, 2014 - BusinessWire - BZX
Zeldes Haeggquist & Eck, LLP Announces Investigation of Celgene, Inc. 9:01 a.m. Sept. 22, 2014 - BusinessWire - BZX
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
Celgene Appoints Tuomo Pätsi as President of EMEAand Commits to Continue Delivering Innovative Solutionsto Meet Patient Needs Across the Region 8:02 a.m. Sept. 19, 2014 - BusinessWire - BZX
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers 9:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
Critical Alerts For CBS, Imperva Inc, Toyota Motor, Celgene and News Corp Released By InvestorsObserver 9:31 a.m. Sept. 11, 2014 - PR Newswire - PRF
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth 8:55 a.m. Sept. 8, 2014 - PR Newswire - PRF
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology 9:06 a.m. Sept. 5, 2014 - ACCESSWIRE
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen 8:55 a.m. Sept. 4, 2014 - PR Newswire - PRF
